Tango Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
The session highlighted progress in PRMT5 inhibitor development, with vopimetostat showing promising efficacy and safety in pancreatic cancer and ongoing combination trials with RAS inhibitors. New collaborations and a brain-penetrant compound expand the pipeline, aiming to transform treatment options.
-
Vopimetostat, a selective PRMT5 inhibitor, is advancing through pivotal trials in pancreatic and lung cancers, with strong early efficacy and safety data. Combination studies with RAS inhibitors and new CNS-penetrant candidates are progressing, supported by robust financials.
-
Leadership transition brings continuity, with a focus on advancing vopimetostat toward regulatory approval. Key trials in pancreatic and lung cancer are progressing, with pivotal and combination data expected this year. Pipeline expansion includes TNG456 and TNG961, targeting new indications.
-
Leadership transitioned to Malte Peters, ensuring continuity as the company advances late-stage clinical development for MTAP-deleted cancers. Key milestones include pivotal trials in pancreatic cancer, combination studies with RAS inhibitors, and expansion into glioblastoma, supported by strong financials and FDA-aligned strategies.
Fiscal Year 2025
-
Three clinical programs are advancing, with Vopimetostat showing strong efficacy in pancreatic cancer and a pivotal phase III set for 2026. FDA-aligned trial design, competitive differentiation, and a cash runway into 2028 support execution of key milestones.
-
Vopimetostat shows promising efficacy in MTAP-deleted cancers, with a pivotal second-line pancreatic cancer study design agreed upon by the FDA. Combination studies with RAS inhibitors are progressing rapidly, with key data updates expected next year. Cash runway extends into 2028.
-
Vopimetostat, a selective PRMT5 inhibitor, showed a 27% overall response rate and strong safety in MTAP-deleted cancers, with particularly promising results in second-line pancreatic and histology-agnostic cohorts. A pivotal phase III trial is planned for 2026, supported by new financing and ongoing combination studies.
-
TNG462, a selective PRMT5 inhibitor, is showing promising efficacy and tolerability in MTAP-deleted cancers, with pivotal pancreatic cancer data expected in the second half of the year. Combination trials with RAS inhibitors are underway, and a brain-penetrant PRMT5 inhibitor is advancing for glioblastoma.
-
The session highlighted advances in synthetic lethality, with TNG462 and TNG456 advancing in MTAP-deleted cancers and glioblastoma, respectively. Durable responses, strong tolerability, and a focus on RAS-mutant combinations position the pipeline for pivotal studies and competitive leadership.
-
The discussion highlighted progress in PRMT5 inhibitor development, emphasizing durability of response and differentiation between brain-penetrant and non-penetrant molecules. Upcoming data will focus on pancreatic and lung cancer, with combination strategies and new programs targeting resistance to immunotherapy.
-
The conference highlighted strong progress in PRMT5 inhibitor development, with TNG462 advancing toward phase 3 in lung and pancreatic cancer and new brain-penetrant candidates entering the clinic. Combination strategies and a robust pipeline, including the CoREST program, position the company as a front runner.
Fiscal Year 2024
-
The session highlighted advances in synthetic lethality for oncology, with TNG462 showing promising efficacy and safety in MTAP-deleted cancers, outperforming competitors in early data. Upcoming 2025 updates will provide mature results and clarify monotherapy and combination opportunities.
-
The discussion highlighted the promise of next-generation PRMT5 inhibitors for MTAP-deleted cancers, with a focus on selectivity, durability of response, and combination strategies. Recent competitor data support the clinical potential, and upcoming trial results will inform future development paths.
-
PRMT5 is a validated oncology target, with second-generation inhibitors showing promise in MTAP-deleted tumors. Two lead molecules are advancing in phase I trials, with updates expected in late 2024. The pipeline includes a CoREST inhibitor for STK11-mutant cancers, and funding is secured into 2027.
-
The company is advancing two PRMT5 inhibitors for MTAP-deleted cancers, both now in dose expansion, with key clinical updates expected in the second half of the year. A coREST inhibitor for STK11 mutant tumors is also progressing, and the cash runway extends into 2027.